Instil Bio Inc(TIL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:26 AM ET (Korea 9/11 20:26)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.47 | Insider Own | 38.58% | Shs Outstand | 6.8M | Perf Week | -4.23% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.2M | Perf Month | -1.74% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | - | Inst Own | 28.35% | Short Float | 4.23% | Perf Quarter | -7.77% |
| Income | -0.03B | P/S | - | EPS this Y | - | Inst Trans | 0.3% | Short Ratio | 14.92 | Perf Half Y | -18.49% |
| Sales | 0.00B | P/B | 0.46 | EPS next 5Y | - | ROA | -14.13% | Short Interest | 0.18M | Perf YTD | -33.09% |
| Book/sh | 15.83 | P/C | 0.71 | EPS past 3/5Y | 32.28% -12.7% | ROE | -25.33% | 52W High | -72.21% ($26.48) | Perf Year | -67.97% |
| Cash/sh | 10.31 | P/FCF | - | Sales past 3/5Y | - | ROIC | -15.58% | 52W Low | 29.81% ($5.67) | Perf 3Y | -20.54% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 65.39% | Gross Margin | - | Volatility(W/M) | 2.37% 2.81% | Perf 5Y | -98.03% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 21.67 | EPS Q/Q | 80.45% | Profit Margin | - | RSI (14) | 43.72 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.67 | Sales Q/Q | - | SMA20 | -2.76% ($7.57) | Beta | 1.94 | Target Price | $7 |
| Payout | - | Debt/Eq | 0.81 | Earnings | 2026/8/13 | SMA50 | -1.66% ($7.48) | Rel Volume | 0.96 | Prev Close | $7.58 |
| Employees | 17 | LT Debt/Eq | 0.81 | EPS/Sales Surpr. | -80% - | SMA200 | -12.14% ($8.38) | Avg Volume(3M) | 0.01M | Price | $7.36 |
| IPO | 2021/3/19 | Option/Short | No/Yes | Trades | 153 | Volume | 11,379 | Change | -2.9% |
Company
TIL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A clinical-stage biotech company that was developing Tumor-Infiltrating Lymphocyte (TIL) therapy. The company is now at a strategic pivot point, having halted its existing pipeline and is seeking to acquire or in-license new therapeutic candidates, leveraging its strong cash position.
Over the past 1 year, on the lower side
72% below its 1-year high.
TIL has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -20.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 28.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
DFAC 0.00%
DFAS 0.00%
AVSC 0.00%
VTI 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
VCIT 69.0B
VCSH 44.8B
DYNF 41.7B
JPST 41.5B
USMV 23.8BIt ranks #4 in the industry
Based on market cap of $50M.
TIL $50M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is TIL?
TIL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TIL?
The market cap of TIL is approximately $50M, ranking 4,937 within its sector.
What is the 52-week high and low for TIL?
TIL has recorded a 52-week high of $26.48 and a low of $5.67.
